Stockscreener 앱 받기
7.6338
2.42%
-0.2162
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Can REGENXBIO Inc. expand its profit marginsSafe Growth Small Cap Picks - thegnnews.com
These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts - Yahoo Finance
REGENXBIO Inc. recovery potential after sell offBuy Entry Confirmation Based on Technical Analysis - Newser
When is the best time to exit REGENXBIO Inc.Breakout Screener With Alert Based Timing - Newser
REGENXBIO (NASDAQ:RGNX) Stock Price Passes Below Fifty Day Moving Average on Disappointing Earnings - Defense World
Is REGENXBIO Inc. stock a buy or sellElite Portfolio Components - thegnnews.com
Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026 - MSN
Regenxbio: RBC Capital Maintains Outperform, PT Down to $17 from $21 - AInvest
Can REGENXBIO Inc. hit a new high this monthPredictable Entry Strategy With Technical Backing - Newser
Regenxbio price target lowered to $17 from $21 at RBC Capital - TipRanks
RBC Capital lowers Regenxbio stock price target to $17 on quarterly results - Investing.com Australia
Regenxbio's Q2 2025: Key Contradictions on RGX-121 Approval, Manufacturing Plans, and Pivotal Study Design - AInvest
REGENXBIO Inc. (RGNX): Navigating Q2 2025 Challenges with a High-Stakes Gene Therapy Pipeline - AInvest
RBC Cuts Price Target on REGENXBIO to $17 From $21, Keeps Outperform, Speculative Risk - MarketScreener
Transcript : REGENXBIO Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Regenxbio 2025 Q2 Earnings Wider Losses Amid Progress in Gene Therapy Pipeline - AInvest
REGENXBIO Reports Q2 2025 Financial Results and Progress - TipRanks
Forecasting REGENXBIO Inc. price range with options dataExit Strategy Guide With Risk Control Plan - Newser
Regenxbio Inc. shares rise 1.27% after-hours following the initiation of a pivotal Phase IIb/III clinical trial for diabetic retinopathy. - AInvest
Regenxbio: Q2 Earnings Snapshot - The Washington Post
Regenxbio stock maintains Outperform rating at Raymond James on solid cash runway - Investing.com Nigeria
Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips - Investing.com
Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips By Investing.com - Investing.com Canada
Regenxbio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
XtalPi inks pact with Greg Verdine’s DoveTree; Regenxbio, AbbVie update deal - Endpoints News
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy - TipRanks
Regenxbio Incphase IIb/III trial to be initiated for diabetic retinopathy - MarketScreener
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
RegenXBio and AbbVie Amend Collaboration Agreement - TipRanks
Regenxbio Inc earnings missed by $0.44, revenue fell short of estimates - Investing.com South Africa
Biotech firm Regenxbio Q2 net loss widens - MarketScreener
REGENXBIO to advance diabetic retinopathy treatment to Phase IIb/III trial By Investing.com - Investing.com Australia
REGENXBIO Accelerates 3 Late-Stage Gene Therapies: FDA Review, Duchenne Trial Progress, and $363M War Chest - Stock Titan
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy - Yahoo Finance
Analyzing drawdowns of REGENXBIO Inc. with statistical toolsLong-Term Safety Investment Analysis Report - Newser
REGENXBIO Inc. Stock Analysis and ForecastAchieve breakthrough performance with smart picks - Jammu Links News
What catalysts could drive REGENXBIO Inc. stock higher in 2025Get alerts on top growth stocks daily - Jammu Links News
What is the dividend policy of REGENXBIO Inc. stockSkyrocketing investment returns - Jammu Links News
How many analysts rate REGENXBIO Inc. as a “Buy”Phenomenal returns - Jammu Links News
What is REGENXBIO Inc. company’s growth strategyAchieve consistent profits with smart trading - Jammu Links News
How strong is REGENXBIO Inc. company’s balance sheetExceptional ROI - Jammu Links News
What institutional investors are buying REGENXBIO Inc. stockFast-track wealth growth - Jammu Links News
Is REGENXBIO Inc. a growth stock or a value stockOutstanding capital returns - Jammu Links News
When is REGENXBIO Inc. stock expected to show significant growthExceptional financial outcomes - Jammu Links News
How volatile is REGENXBIO Inc. stock compared to the marketUnlock powerful portfolio management tools - Jammu Links News
Clear Street Initiates Regenxbio(RGNX.US) With Buy Rating, Announces Target Price $50 - 富途牛牛
What makes REGENXBIO Inc. stock price move sharplyTrack emerging stocks with high growth potential - Jammu Links News
What drives REGENXBIO Inc. stock priceTriple returns potential - Jammu Links News
REGENXBIO to Discuss Q2 2025 Financial Results and Operational Highlights on August 7 - AInvest
Should I hold or sell REGENXBIO Inc. stock in 2025Daily Trading Updates For Smart Trading - Jammu Links News
Bank of New York Mellon Corp Cuts Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO Publishes Preclinical Data Highlighting RGX-202’s Potential for Duchenne Muscular Dystrophy - Insider Monkey
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights - 富途牛牛
REGENXBIO Q2 financial results and operational highlights on August 7, 2025. - AInvest
REGENXBIO to Discuss Q2 2025 Financial Results and Operational Highlights on August 7 Conference Call - AInvest
1.52%
0.80%
자본화:
|
볼륨(24시간):